Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146403 · ClinicalTrials.gov registry record · Phase 2
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Phase 2 study, sponsored by Genocea Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03146403: Clinical Trial Phase 2 study, sponsored by Genocea Biosciences.
NCT03146403 is a Phase 2 study that was terminated before completion, run by Genocea Biosciences. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03146403, a Phase 2 study, was terminated before completion, sponsored by Genocea Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
Primary Outcome
Subject-reported via electronic diary
Interventions
- BIOLOGICAL Matrix-M2
- BIOLOGICAL GEN-003
- OTHER 0.9% normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2018-06-11 |
| Phase | Phase 2 |
Why NCT03146403 stopped before completion
NCT03146403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Matrix-M2 is the first listed.
NCT03146403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03146403 about?
NCT03146403 is a clinical study titled "Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection". The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
What is the current status of trial NCT03146403?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-05-24. Estimated completion is 2018-06-11.
What interventions are being tested in trial NCT03146403?
The interventions under investigation include: Matrix-M2 (BIOLOGICAL), GEN-003 (BIOLOGICAL), 0.9% normal saline (OTHER).
Who is sponsoring clinical trial NCT03146403?
This trial is sponsored by Genocea Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03146403's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI